2.77
+0.7509(+37.17%)
Currency In USD
| Previous Close | 2.02 |
| Open | 3.01 |
| Day High | 4.24 |
| Day Low | 2.44 |
| 52-Week High | 4.25 |
| 52-Week Low | 0.64 |
| Volume | 63.86M |
| Average Volume | 870,172 |
| Market Cap | 7.44M |
| PE | -1.91 |
| EPS | -1.45 |
| Moving Average 50 Days | 1.22 |
| Moving Average 200 Days | 1.65 |
| Change | 0.75 |
If you invested $1000 in Lixte Biotechnology Holdings, Inc. (LIXT) 10 years ago, it would be worth $177.62 as of July 04, 2025 at a share price of $2.771. Whereas If you bought $1000 worth of Lixte Biotechnology Holdings, Inc. (LIXT) shares 5 years ago, it would be worth $51.31 as of July 04, 2025 at a share price of $2.771.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market
GlobeNewswire Inc.
Jul 02, 2025 8:05 PM GMT
PASADENA, CALIF, July 02, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a clinical stage pharmaceutical company, today announced the closing of a private placement with accredited investors for the purc
Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market
GlobeNewswire Inc.
Jul 01, 2025 8:15 PM GMT
PASADENA, CALIF, July 01, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a clinical stage pharmaceutical company, today announced that, on June 30, 2025 intraday, it entered into a definitive agreement w
LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100
GlobeNewswire Inc.
Mar 31, 2025 12:30 PM GMT
Pre-Clinical Study in Collaboration with Netherlands Cancer Instituteis in addition to LIXTE’s Ongoing Clinical Trials for Ovarian and Colorectal Cancers PASADENA, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXT